At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02367 GIANT BIOGENE
Trading 04-29 14:54:19
29.640
+0.240
+0.82%
High29.780Low29.320Vol3.27M
Open29.400D1 Closing29.400Amplitude1.56%
Mkt Cap31.48BTradable Cap31.48BTotal Shares1.06B
T/O96.55MT/O Rate0.31%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Giant Biogene Shares Extend Rally with Over 7% Surge Following CCTV Factory Feature
Stock News  ·  04-21
Giant Biogene Shares Extend Rally with Over 7% Surge Following CCTV Factory Feature
GIANT BIOGENE Cancels 9.2 Million Repurchased Shares
Stock News  ·  04-20
GIANT BIOGENE Cancels 9.2 Million Repurchased Shares
Giant Biogene files HKEX return disclosing share repurchase at HKD 35.94 each
Reuters  ·  04-20
Giant Biogene files HKEX return disclosing share repurchase at HKD 35.94 each
Stock Track | Giant Biogene Soars 5.49% Intraday as Market Sentiment Recovers After Annual Results Release
Stock Track  ·  04-20
Stock Track | Giant Biogene Soars 5.49% Intraday as Market Sentiment Recovers After Annual Results Release
Giant Biogene names Au-Yeung Nelly as Joint Company Secretary, Authorised Representative and Process Agent
Bulletin Express  ·  04-08
Giant Biogene names Au-Yeung Nelly as Joint Company Secretary, Authorised Representative and Process Agent
GIANT BIOGENE Appoints Co-Company Secretary
Stock News  ·  04-08
GIANT BIOGENE Appoints Co-Company Secretary
Giant Biogene appoints Au-Yeung Nelly as joint company secretary, authorized representative and process agent
Reuters  ·  04-08
Giant Biogene appoints Au-Yeung Nelly as joint company secretary, authorized representative and process agent
GIANT BIOGENE Keeps Issued Share Count Steady at 1.07 Billion in March; Public Float Remains Compliant
Bulletin Express  ·  04-02
GIANT BIOGENE Keeps Issued Share Count Steady at 1.07 Billion in March; Public Float Remains Compliant
GIANT BIOGENE Reports First Post-IPO Profit Decline; Can Its Foray into Medical Aesthetics Weave a New Growth Tale?
Deep News  ·  04-01
GIANT BIOGENE Reports First Post-IPO Profit Decline; Can Its Foray into Medical Aesthetics Weave a New Growth Tale?
Giant Biogene Holding SEHK 2367 Valuation Check After Weaker Earnings And Adjusted Dividends
Simply Wall St.  ·  03-28
Giant Biogene Holding SEHK 2367 Valuation Check After Weaker Earnings And Adjusted Dividends
Analysis of GIANT BIOGENE's 2025 Annual Report: Growth Myth Fades, Six Major Risks Highlight Transition Challenges
Deep News  ·  03-27
Analysis of GIANT BIOGENE's 2025 Annual Report: Growth Myth Fades, Six Major Risks Highlight Transition Challenges
Time To Worry? Analysts Are Downgrading Their Giant Biogene Holding Co., Ltd. (HKG:2367) Outlook
Simply Wall St.  ·  03-25
Time To Worry? Analysts Are Downgrading Their Giant Biogene Holding Co., Ltd. (HKG:2367) Outlook
Stock Track | GIANT BIOGENE Plummets 5.15% Intraday After CICC Cuts Profit Forecasts and Target Price
Stock Track  ·  03-23
Stock Track | GIANT BIOGENE Plummets 5.15% Intraday After CICC Cuts Profit Forecasts and Target Price
CICC Trims GIANT BIOGENE (02367) Target Price to HK$49, Keeps "Outperform" Rating
Stock News  ·  03-23
CICC Trims GIANT BIOGENE (02367) Target Price to HK$49, Keeps "Outperform" Rating
Giant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives
Simply Wall St.  ·  03-20
Giant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives
Giant Biogene's Recovery Expected in Second Half, Citi Lowers Target Price to HK$37
Stock News  ·  03-20
Giant Biogene's Recovery Expected in Second Half, Citi Lowers Target Price to HK$37
Giant Biogene Faces Growth Concerns Following Hyaluronic Acid-Collagen Dispute
Deep News  ·  03-20
Giant Biogene Faces Growth Concerns Following Hyaluronic Acid-Collagen Dispute
GIANT BIOGENE Maintains "Outperform" Rating from CICC Amid Product Expansion
Stock News  ·  03-20
GIANT BIOGENE Maintains "Outperform" Rating from CICC Amid Product Expansion
Giant Biogene (2367.HK) 2025 Results: Revenue Stable at RMB 5.52 Billion, Net Profit Down 7.1%, Declares RMB 1.21 Dividend per Share
Bulletin Express  ·  03-19
Giant Biogene (2367.HK) 2025 Results: Revenue Stable at RMB 5.52 Billion, Net Profit Down 7.1%, Declares RMB 1.21 Dividend per Share
Giant Biogene (02367) Declares RMB 0.6714 Special Dividend for FY 2025; Payment Slated for 25 June 2026
Bulletin Express  ·  03-19
Giant Biogene (02367) Declares RMB 0.6714 Special Dividend for FY 2025; Payment Slated for 25 June 2026
No data available

Introduction

Company Name.
GIANT BIOGENE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Giant Biogene Holding Co Ltd is an investment holding company primarily engaged in the research, development, manufacture and sale of bioactive material-based beauty and health products. The Company's main products include professional skin treatment products such as functional skincare products and medical dressings, as well as functional foods and others. The Company primarily conducts its businesses in domestic market.
Issue price:
--